Active Ingredient History

  • Now
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor used in combination with cobicistat, emtricitabine and tenofovir alafenamid (GENVOYA®) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection.   NCATS

  • SMILES: COC1=CC2=C(C=C1CC3=CC=CC(Cl)=C3F)C(=O)C(=CN2[C@H](CO)C(C)C)C(O)=O
  • Mol. Mass: 447.884
  • ALogP: 4.28
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( emtricitabine (emtriva), tenofovir alafenamide (genvoya), cobicistat (stribild), elvitegravir (vitekta) - other name: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide )
( tenofovir (viread), emtricitabine (emtriva), cobicistat (stribild), elvitegravir (vitekta) - other name: cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate )
6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | elvitegravir | elvitégravir | elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide | elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate | evg | gs9137 | gs 9137 | gs-9137 | jtk303 | jtk 303 | jtk-303 | vitekta


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue